Genesis Therapeutics
Uses deep learning and molecular simulations to discover small molecule drugs.
What they do
Genesis Therapeutics develops deep learning models for molecular generation and property prediction. The company operates their proprietary platform to design novel small molecule drug candidates against previously undruggable targets, partnering with major pharmaceutical companies.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- AI drug discovery
- Product type
- Platform software
- Stage
- Series B
- Headquarters
- Burlingame, United States
- Region
- North America
- Founded
- 2019
- Total funding
- $280M raised
Notable investors: Andreessen Horowitz, Rock Springs Capital, Fidelity Management, T. Rowe Price.